Literature DB >> 3496538

Association between lupus psychosis and anti-ribosomal P protein antibodies.

E Bonfa, S J Golombek, L D Kaufman, S Skelly, H Weissbach, N Brot, K B Elkon.   

Abstract

In 18 of 20 patients with psychosis secondary to systemic lupus erythematosus (SLE), autoantibodies to ribosomal P proteins were detected by immunoblotting and measured with a new radioimmunoassay using a synthetic peptide as antigen. The frequency of anti-P was not increased in patients with other central nervous system manifestations of SLE (3 of 20, by radioimmunoassay), in patients with transient behavioral abnormalities due to SLE (none of 8), in patients with psychosis who did not have SLE (none of 13), or in normal controls (none of 20). In four of five paired serum samples, anti-P-peptide antibody levels increased 5-fold to 30-fold during the active phase of lupus psychosis. Longitudinal studies of anti-P activity in two patients with psychosis revealed that anti-P levels increased before and during the active phases of psychosis but not during sepsis or other exacerbations of SLE, and that the elevations were selective for anti-P antibodies, as opposed to anti-DNA antibodies. Longitudinal studies of anti-P activity in two patients with anti-P but without psychosis showed less than threefold changes in anti-P levels despite exacerbations of disease. We conclude that anti-P is associated with lupus psychosis and that synthetic peptide antigens may be useful for the detection and measurement of autoantibodies to intracellular proteins.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3496538     DOI: 10.1056/NEJM198707303170503

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  128 in total

Review 1.  Neuropsychiatric lupus.

Authors:  J G Hanly
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

Review 2.  Systemic lupus erythematosus.

Authors:  M S Klein-Gitelman; M L Miller
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

3.  Technical and clinical evaluation of anti-ribosomal P protein immunoassays.

Authors:  M Mahler; K Kessenbrock; J Raats; M J Fritzler
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

4.  Role of antigen selectivity in autoimmune responses to the Ku (p70/p80) antigen.

Authors:  W H Reeves; Z M Sthoeger; R G Lahita
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 5.  Lupus-related hepatitis: complication of lupus or autoimmune association? Case report and review of the literature.

Authors:  Roop Kaw; Carmen Gota; Ana Bennett; David Barnes; Leonard Calabrese
Journal:  Dig Dis Sci       Date:  2006-04       Impact factor: 3.199

Review 6.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

7.  Clinical and autoantibody correlations in Orientals with systemic lupus erythematosus.

Authors:  M L Boey; C L Peebles; G Tsay; P H Feng; E M Tan
Journal:  Ann Rheum Dis       Date:  1988-11       Impact factor: 19.103

8.  Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course.

Authors:  A J Swaak; R Q Hintzen; V Huysen; H G van den Brink; J T Smeenk
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

Review 9.  Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.

Authors:  Virginia Fernandes Moça Trevisani; Aldemar A Castro; João Ferreira Neves Neto; Alvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

10.  Organic brain syndrome with psychosis as an initial manifestation of systemic lupus erythematosus in an elderly woman.

Authors:  M E Mavrikakis; L G Antoniades; J B Germanides; D Sotou; A Rassidakis
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.